Biomarker targets and novel therapeutics.
Clouser
Mary
M
Division of Women's Cancers, Arizona Cancer Center, The University of Arizona, Tucson, AZ, USA.
Hess
Lisa M
LM
Chambers
Setsuko K
SK
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors*; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015201:Meta-Analysis as Topic; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009944:Organoplatinum Compounds / Q000494:pharmacology / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000628:therapy; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015507:Drugs, Investigational; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases